TriangleSacituzumab Govitecan (NCT05884320)
Sacituzumab Govitecan trial for Gland (NCT05884320). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with recurrent or metastatic salivary-gland cancer unsuitable for definitive surgery or radiation. Eligible types are recently progressing adenoid-cystic cancer, salivary-duct cancer, or intermediate/high-grade adenocarcinoma NOS or mucoepidermoid cancer. Prior-treatment requirements vary; HER2-positive non-adenoid-cystic tumors require prior HER2 therapy or a contraindication.
The idea: sacituzumab govitecan carries a DNA-damaging payload to TROP2-bearing cells. Both cohorts receive infusions on days one and eight each cycle. Researchers measure response, survival, and safety.
This phase 2 study plans 30 patients. Renata Ferrarotto leads at MD Anderson, Houston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.